Vincent Alford is a notable inventor based in Lake Grove, NY (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target specific biological functions.

Latest Patents

Vincent Alford holds two patents that showcase his innovative work. The first patent is for "Substituted pyrimidines as matrix metalloproteinase-9 hemopexin domain inhibitors." This invention relates to substituted pyrimidine compounds that selectively target the hemopexin domain of matrix metalloproteinase 9 (MMP-9) without inhibiting the protease's catalytic functions. The invention also includes methods for treating cancer in patients using these compounds. The second patent is for "Substituted quinazolines as matrix metalloproteinase-9 hemopexin domain inhibitors," which involves a compound designed to achieve similar therapeutic effects.

Career Highlights

Vincent Alford is affiliated with the State University of New York, where he has contributed to research and development in the field of medicinal chemistry. His work has implications for cancer treatment, showcasing his commitment to advancing healthcare through innovative solutions.

Collaborations

Vincent has collaborated with notable colleagues, including Iwao Ojima and Anushree Kamath, who have contributed to his research endeavors.

Conclusion

Vincent Alford's work in developing targeted inhibitors for matrix metalloproteinases represents a significant advancement in pharmaceutical chemistry. His contributions are poised to impact cancer treatment positively.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to [email protected]